文献速递儿科与产科急症

无活力婴儿脐带挤奶的两年结局:MINVI随机临床试验的二次分析

Two-Year Outcomes of Umbilical Cord Milking in Nonvigorous Infants: A Secondary Analysis of the MINVI Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-07-01
一句话结论无活力近足月及足月儿出生时接受脐带挤奶与早期脐带结扎相比,2岁时ASQ-3及M-CHAT-R/F评分无显著差异,提示脐带挤奶不增加远期神经发育风险。

该研究为MINVI整群随机交叉试验的二次分析,纳入美国、加拿大、波兰10个医疗中心的35至42周妊娠无活力新生儿,随机接受脐带挤奶(UCM)或早期脐带结扎(ECC)。在1730名新生儿中,971名(81%)有2岁时ASQ-3评分或死亡数据,927名(77%)有M-CHAT-R/F评分或死亡数据。UCM组与ECC组ASQ-3总分中位数相似(255 vs 255,P=0.87),各子域无显著差异;M-CHAT-R/F中高风险比例亦相似(UCM 9% vs ECC 8%,P=0.86)。结合既往报告的短期获益,该随访提示UCM是一种可行、无成本的干预,不增加无活力近足月及足月新生儿的远期神经发育风险。

要点

  • 在无活力近足月及足月儿中,出生时UCM与ECC相比,2岁时ASQ-3总分中位数相似(255 vs 255,P=0.87)。
  • UCM组与ECC组2岁时M-CHAT-R/F中高风险比例相似(9% vs 8%,P=0.86)。
  • UCM组ASQ-3各子域评分与ECC组无显著差异。
  • 结合既往短期获益,作者认为UCM是可行、无成本且不增加远期神经发育风险的干预。
  • 该分析纳入971名(81%)有ASQ-3数据或死亡儿童,927名(77%)有M-CHAT-R/F数据或死亡儿童。

适用人群与场景

  • 出生时胎龄35至42周、无活力的近足月及足月婴儿。
  • 家庭同意完成至2岁的发展筛查问卷。

研究设计与关键结果

  • 研究类型:整群随机交叉试验的二次分析;主试验在美国、加拿大、波兰10个医疗中心进行,主试验时间为2019年1月5日至2021年6月1日,二次分析时间为2021年1月9日至2023年9月25日,随访于2023年9月26日结束。
  • 主试验共1730名新生儿;971名(81%)有2岁时ASQ-3评分或于2岁前死亡,927名(77%)有M-CHAT-R/F评分或于2岁前死亡。
  • 两组母婴特征相似,出生胎龄中位数均为39周(IQR 38-40);UCM组女性224例(45%),ECC组女性201例(43%)。
  • 主要结局:ASQ-3总分中位数UCM组255(IQR 225-280)vs ECC组255(IQR 230-280),P=0.87;ASQ-3各子域无显著差异。
  • M-CHAT-R/F中高风险评分:UCM组9%(45/486)vs ECC组8%(37/441),P=0.86。

证据类型、等级与局限

  • 证据类型:随机临床试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,结合既往报告的短期重要获益,UCM是一种可行、无成本的干预,不增加无活力近足月及足月新生儿的远期神经发育风险。

指南或共识出处

  • 临床试验注册号:ClinicalTrials.gov NCT03631940。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Compared with early cord clamping (ECC), umbilical cord milking (UCM) reduces delivery room cardiorespiratory support, hypoxic-ischemic encephalopathy, and therapeutic hypothermia in nonvigorous near-term and full-term infants. However, UCM postdischarge outcomes are not known.

OBJECTIVE: To determine the 2-year outcomes of children randomized to UCM or ECC at birth in the Milking in Nonvigorous Infants (MINVI) trial.

DESIGN, SETTING, AND PARTICIPANTS: A secondary analysis to evaluate longer-term outcomes of a cluster-randomized crossover trial was conducted from January 9, 2021, to September 25, 2023. The primary trial took place in 10 medical centers in the US, Canada, and Poland from January 5, 2019, to June 1, 2021, and hypothesized that UCM would reduce admission to the neonatal intensive care unit compared with ECC; follow-up concluded September 26, 2023. The population included near-term and full-term infants aged 35 to 42 weeks' gestation at birth who were nonvigorous; families provided consent to complete developmental screening questionnaires through age 2 years.

INTERVENTION: UCM and ECC.

MAIN OUTCOMES AND MEASURES: Ages and Stages Questionnaire, 3rd Edition (ASQ-3) and Modified Checklist for Autism in Toddlers, Revised/Follow-Up (M-CHAT-R/F) questionnaires at ages 22 to 26 months. Intention-to-treat analysis and per-protocol analyses were used.

RESULTS: Among 1730 newborns from the primary trial, long-term outcomes were evaluated in 971 children (81%) who had ASQ-3 scores available at 2 years or died before age 2 years and 927 children (77%) who had M-CHAT-R/F scores or died before age 2 years. Maternal and neonatal characteristics by treatment group were similar, with median birth gestational age of 39 (IQR, 38-40) weeks in both groups; 224 infants (45%) in the UCM group and 201 (43%) in the ECC group were female. The median ASQ-3 total scores were similar (UCM: 255 [IQR, 225-280] vs ECC: 255 [IQR, 230-280]; P = .87), with no significant differences in the ASQ-3 subdomains. Medium- to high-risk M-CHAT-R/F scores were also similar (UCM, 9% [45 of 486] vs ECC, 8% [37 of 441]; P = .86).

CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial among late near-term and full-term infants who were nonvigorous at birth, ASQ-3 scores at age 2 years were not significantly different between the UCM and ECC groups. Combined with previously reported important short-term benefits, this follow-up study suggests UCM is a feasible, no-cost intervention without longer-term neurodevelopmental risks of cord milking in nonvigorous near-term and term newborns.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03631940.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Katheria AC, El Ghormli L, Clark E, et al. Two-Year Outcomes of Umbilical Cord Milking in Nonvigorous Infants: A Secondary Analysis of the MINVI Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38949814. doi:10.1001/jamanetworkopen.2024.16870

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。